List view / Grid view
AI is set to transform drug development in 2025, streamlining processes and opening new possibilities. Learn how this technology is transforming clinical trials and reshaping the pharmaceutical industry.
The path to faster breakthroughs in precision medicine begins with overcoming the complexities of multi-modal data. Discover how innovative solutions are enabling more personalised treatments.
Results from Pistoia Alliance’s Lab of the Future survey has shared important findings about the challenges life science companies face.
In this four-part series, Dr Raminderpal Singh will discuss the challenges surrounding limited data quality, and some pragmatic solutions. In this second article, he discusses the problems that occur when using data of poor quality.
In this four-part series, Dr Singh will discuss the challenges surrounding limited data quality, and some pragmatic solutions. In this first article, the key attributes that define data quality and its requirement for data scientists are elucidated.
Tune in to this episode where we explore how innovative assays and human-relevant cell models are transforming toxicity screening in drug development.
A novel screening tool may increase the five-year survival rate of hepatocellular carcinoma patients to 90 percent.
Researchers have developed a 3D approach to improve the characterisation of pancreatic intraepithelial neoplasias.
As we move towards more generalised AI models, neural networks and natural language interfaces, we’re starting to see machine learning take the place of higher order reasoning and data analysis “sense making.” Traditional scientific inquiry has typically been about asking specific questions of a specific model system under specific conditions.…
Natural products play an underappreciated role in drug discovery. Tandem mass spectrometry (MS/MS)-based metabolomics coupled with machine learning is allowing new, highly diverse molecules from natural products to be identified, revealing bioactive compounds and pinpointing promising drug targets. The additional dimension provided by trapped ion mobility (TIMS) enables researchers to…
In this Q&A, Dr Gerard Wong elucidates the inflammatory capacity of fragmented viral components from the perspective of supramolecular self-organisation.
Researchers conducted a proteogenomic characterisation and found that drug exposure changes drug sensitivity.
The computer model enables a better understanding of how drugs affect fibroblasts and finds a promising candidate to prevent heart scarring.
The ML algorithm explores how genetic mutations collectively influence a tumour’s reaction to drugs impeding DNA replication.
Dr Ketan Patel, Clarivate, shares his insights about the use of Real-World Data and genomic biomarker data and discusses how researchers can use these to better detect and diagnose diseases.
